BCL6 and cancer: A recent study showed BCL6, whose translocation is a BN2 hallmark, requires LSD1 for lymphomagenesis [26] and the LSD1 inhibitor seclidemstat is in cancer clinical trials (NCT04734990, NCT03600649).